Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by fouremmon Oct 23, 2015 3:21pm
177 Views
Post# 24221972

RE:fourem on the scam MB posted summin i disagree with:

RE:fourem on the scam MB posted summin i disagree with:Hey oth, I'm not sure how you get apologist out of my post on the other board but your opinion, fair enough.  My post was more directed at what is going on with the stock right now and probably until January so keeping that in mind..

a) although I agree that if BetOnMace had FDA approval the stock would be higher I don't think that it is now causing people to sell (it has been a fact for quite awhile now) and given the lack of volume in RVX trade I don't think this has been a big deal in the eyes of the market.  I think if not getting FDA approval was a big deal in the eyes of the market RVX would have sold off on much larger volume.  I'm not sure that I put that much credence in the idea that FDA non-approval constitutes commentary on the chances of BetOnMace succeeding.  I don't really think the FDA really cares whether it succeeds or not.  Why should they, not their money? What they care about most is whether trial participants will be safe.  With RVX's safety record I don't think safety is a concern, that's why I lean more to the idea that at least some of the problem with the FDA timeliness is administrative in nature.  Just as an aside, I agree with a point you made awhile back that it is very doubtful that FDA scientists would have problems understanding the science.

Wrt 5pt vs 3pt MACE, BDAZ well covered this in other posts. 

b)while I agree with that in general I don't think it has mattered one way or the other to the market.

c)agree

I still think that the over riding factors, right now, in RVX price/volume are in general a wait and see attitude coupled with impending tax loss selling.  I guess we shall see come January.
Bullboard Posts